Previous 10 | Next 10 |
Valneva SE (VALN) is expected to report $-0.36 for Q2 2023
2023-08-14 06:42:08 ET More on Valneva Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race Valneva COVID shot shelf life extended; gets EMA nod for booster; shows efficacy in trials Valneva's single-shot chikungunya vaccine VLA1553 gets FDA priority revie...
2023-07-18 04:17:27 ET Summary Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due to its superior clinical profile. Valneva's VLA1553 demonstrated impressive seroresponse rates and du...
2023-06-20 10:07:39 ET Gainers: DICE Therapeutics ( DICE ) +38% . iCAD ( ICAD ) +17% . Nuwellis ( NUWE ) +14% . Valneva ( VALN ) +14% . Cano Health ( CANO ) +13% . Losers: Surgalign ( SRGA ) -72% . Gracel...
2023-05-18 14:13:29 ET Following a meeting of an advisory panel, the World Health Organization announced its recommendations supporting the use of reformulated COVID vaccines to reflect the currently dominant variants such as XBB.1 Noting that XBB.1 descendent lineages have outnumbered ...
2023-05-06 22:10:49 ET Valneva SE (VALN) Q1 2023 Earnings Conference Call May 04, 2023, 09:00 ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - Chairman, President & CEO Peter Buhler - CFO Conference Call Participants Kevin Strang ...
2023-05-04 14:28:34 ET A panel of experts at the World Health Organization (WHO) is expected to meet on Thursday to discuss whether the current COVID-19 pandemic will remain a global emergency, the U.N. agency's highest alert level. The head of the WHO, Dr. Tedros Adhanom Ghebreyesus, i...
2023-04-06 14:14:11 ET After more than three years, the World Health Organization (WHO) could announce an end to the emergency status of COVID-19 this year, the head of the global body Dr. Tedros Adhanom Ghebreyesus, said Thursday. In early 2020, the WHO named the COVID-19 pandemic a Pu...
2023-03-29 22:56:19 ET Summary Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial. The CHIKV vaccine candidate is on track for PDUFA in August 2023, and the company plans to launch one or two programs i...
2023-03-24 13:36:06 ET Valneva ( NASDAQ: VALN ) and Pfizer ( NYSE: PFE ) have pushed back by a year the end date of a phase 3 trial for their Lyme disease vaccine candidate VLA15. The new estimated completion date for the VALOR trial is December 2025, according to ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 09:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 20:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...